NL1024499A1 - Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen. - Google Patents

Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen.

Info

Publication number: NL1024499A1
Authority: NL; Netherlands
Prior art keywords: treatment; neurodegenerative disorders; thiazole compounds; thiazole; compounds
Prior art date: 2002-10-09

Application number

NL1024499A

Other languages

English (en)

Other versions

NL1024499C2 (nl

Inventor

Yuhpyng Liang Chen

Michael Leon Corman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-09

Filing date

2003-10-09

Publication date

2004-04-13

2003-10-09 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-04-13 Publication of NL1024499A1 publication Critical patent/NL1024499A1/nl

2004-10-13 Application granted granted Critical

2004-10-13 Publication of NL1024499C2 publication Critical patent/NL1024499C2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

NL1024499A 2002-10-09 2003-10-09 Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen. NL1024499C2 (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US41740002P	2002-10-09	2002-10-09
US41740002		2002-10-09
US46320903A	2003-06-17	2003-06-17
US46320903		2003-06-17

Publications (2)

Publication Number	Publication Date
NL1024499A1 true NL1024499A1 (nl)	2004-04-13
NL1024499C2 NL1024499C2 (nl)	2004-10-13

Family

ID=35306299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL1024499A NL1024499C2 (nl)	2002-10-09	2003-10-09	Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen.

Country Status (28)

Country	Link
US (1)	US20040152747A1 (nl)
EP (1)	EP1551815A1 (nl)
JP (1)	JP2006504796A (nl)
KR (1)	KR20050070046A (nl)
CN (1)	CN1688557A (nl)
AP (1)	AP2005003274A0 (nl)
AR (1)	AR043051A1 (nl)
AU (1)	AU2003265068A1 (nl)
BR (1)	BR0314611A (nl)
CA (1)	CA2501803A1 (nl)
CO (1)	CO5550435A2 (nl)
CR (1)	CR7785A (nl)
EC (1)	ECSP055719A (nl)
GT (1)	GT200300219A (nl)
IS (1)	IS7738A (nl)
MA (1)	MA27451A1 (nl)
MX (1)	MXPA05002420A (nl)
NL (1)	NL1024499C2 (nl)
NO (1)	NO20052223L (nl)
OA (1)	OA12937A (nl)
PA (1)	PA8585001A1 (nl)
PE (1)	PE20040640A1 (nl)
PL (1)	PL376171A1 (nl)
TN (1)	TNSN05104A1 (nl)
TW (1)	TW200420550A (nl)
UY (1)	UY28011A1 (nl)
WO (1)	WO2004033439A1 (nl)
ZA (1)	ZA200502841B (nl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2842523A1 (fr) *	2002-07-17	2004-01-23	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2006525990A (ja) *	2003-05-12	2006-11-16	ファイザー・プロダクツ・インク	神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
EP1653952A4 (en) *	2003-08-06	2007-04-04	Pfizer Prod Inc	OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
FR2865206B1 (fr) *	2004-01-16	2009-02-06	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) *	2004-07-22	2006-10-20	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2005073202A1 (fr) *	2004-01-16	2005-08-11	Sanofi-Aventis	Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
FR2865207B1 (fr) *	2004-01-16	2008-10-17	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873374B1 (fr) *	2004-07-22	2006-10-20	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
BRPI0506880A (pt) *	2004-01-16	2007-06-26	Sanofi Aventis	derivados de acilaminotiazol, sua preparação e sua aplicação em terapêutica
WO2005092864A1 (en) *	2004-03-23	2005-10-06	Pfizer Products Inc.	Imidazole compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) *	2004-04-01	2007-05-22	Pfizer Inc	Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en)	2004-04-01	2008-06-10	Pfizer Inc.	Thiazole-amine compounds for the treatment of neurodegenerative disorders
AR050917A1 (es)	2004-08-13	2006-12-06	Amphora Discovery Corp	Compuestos basados en 2-amido-tiazol que presentan actividad inhibidora de enzimas que utilizan atp, y composiciones y usos de los mismos
EA014350B1 (ru)	2005-05-24	2010-10-29	Мерк Сероно С.А.	Производные тиазола и их применение
FR2887879B1 (fr) *	2005-07-01	2008-09-26	Trophos Sa	Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
KR20080040010A (ko) *	2005-09-22	2008-05-07	화이자 프로덕츠 인코포레이티드	신경계 질환 치료용 이미다졸 화합물
US8105581B2 (en)	2005-12-01	2012-01-31	The Scripps Research Institute	Compositions and methods for inducing neuronal differentiation
JP5199885B2 (ja) *	2006-01-18	2013-05-15	アムジエン・インコーポレーテツド	プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物
EP1918286B1 (en) *	2006-11-05	2011-12-21	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) *	2007-01-25	2007-03-07	Univ Sheffield	Compounds and their use
CA2692713A1 (en)	2007-07-17	2009-01-22	Amgen Inc.	Heterocyclic modulators of pkb
AU2008276512A1 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of PKB
CA2731097A1 (en)	2008-07-15	2010-01-21	Novartis Ag	Organic compounds
US8889670B2 (en)	2009-02-18	2014-11-18	Boehringer Ingelheim International Gmbh	Heterocyclic compounds which modulate the CB2 receptor
WO2010126002A1 (ja) *	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) *	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
US9315454B2 (en)	2010-01-15	2016-04-19	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
EP2595959B1 (en)	2010-07-22	2015-11-04	Boehringer Ingelheim International GmbH	Sulfonyl compounds which modulate the cb2 receptor
CN102351854B (zh) *	2011-07-29	2014-06-04	华中科技大学	氨基噻唑衍生物及制备方法和医药用途
CA2899088C (en) *	2013-03-14	2022-12-20	Merck Patent Gmbh	Thiazole and oxazole compounds as glycosidase inhibitors
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103408541B (zh) *	2013-07-16	2015-04-01	浙江医药高等专科学校	吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435573B (zh) *	2013-07-16	2015-04-01	浙江医药高等专科学校	苄基取代的噻唑并环己烷类化合物、其制备方法和用途
GB201401886D0 (en) *	2014-02-04	2014-03-19	Lytix Biopharma As	Neurodegenerative therapies
US11274100B2 (en)	2017-06-21	2022-03-15	Daiichi Sankyo Company, Limited	EP300/CREBBP inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0586537A4 (en) *	1991-05-28	1997-06-25	Merck & Co Inc	Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
CO5021134A1 (es) *	1998-05-01	2001-03-27	Abbott Lab	Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
WO1999057098A2 (en) *	1998-05-01	1999-11-11	Abbott Laboratories	Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
WO2000024392A1 (fr) *	1998-10-26	2000-05-04	Sumitomo Pharmaceuticals Company, Limited	Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) *	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) *	2002-07-17	2004-01-23	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

2003
- 2003-09-29 PL PL03376171A patent/PL376171A1/xx not_active Application Discontinuation
- 2003-09-29 CA CA002501803A patent/CA2501803A1/en not_active Abandoned
- 2003-09-29 KR KR1020057006168A patent/KR20050070046A/ko not_active Application Discontinuation
- 2003-09-29 BR BR0314611-1A patent/BR0314611A/pt not_active IP Right Cessation
- 2003-09-29 EP EP03807933A patent/EP1551815A1/en not_active Withdrawn
- 2003-09-29 AP AP2005003274A patent/AP2005003274A0/xx unknown
- 2003-09-29 OA OA1200500098A patent/OA12937A/en unknown
- 2003-09-29 CN CNA038240106A patent/CN1688557A/zh active Pending
- 2003-09-29 WO PCT/IB2003/004330 patent/WO2004033439A1/en active Application Filing
- 2003-09-29 JP JP2005501002A patent/JP2006504796A/ja active Pending
- 2003-09-29 AU AU2003265068A patent/AU2003265068A1/en not_active Abandoned
- 2003-09-29 MX MXPA05002420A patent/MXPA05002420A/es not_active Application Discontinuation
- 2003-10-03 TW TW092127495A patent/TW200420550A/zh unknown
- 2003-10-07 PE PE2003001021A patent/PE20040640A1/es not_active Application Discontinuation
- 2003-10-08 PA PA20038585001A patent/PA8585001A1/es unknown
- 2003-10-08 AR ARP030103662A patent/AR043051A1/es unknown
- 2003-10-08 US US10/682,686 patent/US20040152747A1/en not_active Abandoned
- 2003-10-09 GT GT200300219A patent/GT200300219A/es unknown
- 2003-10-09 NL NL1024499A patent/NL1024499C2/nl not_active IP Right Cessation
- 2003-10-09 UY UY28011A patent/UY28011A1/es not_active Application Discontinuation
2005
- 2005-03-10 IS IS7738A patent/IS7738A/is unknown
- 2005-04-07 CR CR7785A patent/CR7785A/es not_active Application Discontinuation
- 2005-04-07 EC EC2005005719A patent/ECSP055719A/es unknown
- 2005-04-08 TN TNP2005000104A patent/TNSN05104A1/fr unknown
- 2005-04-08 CO CO05031337A patent/CO5550435A2/es not_active Application Discontinuation
- 2005-04-08 MA MA28206A patent/MA27451A1/fr unknown
- 2005-05-06 NO NO20052223A patent/NO20052223L/no unknown
2006
- 2006-01-17 ZA ZA200502841A patent/ZA200502841B/en unknown

Also Published As

Publication number	Publication date
ZA200502841B (en)	2006-03-29
EP1551815A1 (en)	2005-07-13
CN1688557A (zh)	2005-10-26
GT200300219A (es)	2004-05-18
AR043051A1 (es)	2005-07-13
ECSP055719A (es)	2005-07-06
TW200420550A (en)	2004-10-16
PA8585001A1 (es)	2004-12-16
MA27451A1 (fr)	2005-07-01
MXPA05002420A (es)	2005-10-05
BR0314611A (pt)	2005-07-26
PL376171A1 (en)	2005-12-27
KR20050070046A (ko)	2005-07-05
CR7785A (es)	2005-07-08
AP2005003274A0 (en)	2005-06-30
NL1024499C2 (nl)	2004-10-13
CA2501803A1 (en)	2004-04-22
OA12937A (en)	2006-10-13
AU2003265068A1 (en)	2004-05-04
NO20052223D0 (no)	2005-05-06
IS7738A (is)	2005-03-10
CO5550435A2 (es)	2005-08-31
UY28011A1 (es)	2004-04-30
NO20052223L (no)	2005-07-04
US20040152747A1 (en)	2004-08-05
PE20040640A1 (es)	2004-09-15
JP2006504796A (ja)	2006-02-09
TNSN05104A1 (fr)	2007-05-14
WO2004033439A1 (en)	2004-04-22

Publication	Publication Date	Title
NL1024499A1 (nl)	2004-04-13	Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen.
NL1026892A1 (nl)	2005-02-28	ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie.
NL1028598A1 (nl)	2005-09-26	Imidazoolverbindingen voor de behandeling van neurodegeneratieve ziekten.
NL1026329A1 (nl)	2004-12-07	2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
NL1026327A1 (nl)	2004-12-07	2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
NL1025071A1 (nl)	2004-06-22	Verbindingen voor de behandeling van abnormale celgroei.
NL1028086A1 (nl)	2005-07-25	Sulfonamidederivaten voor de behandeling van ziekten.
NL1026203A1 (nl)	2004-11-16	Verbindingen toepasbaar voor de behandeling van ziekten.
NO20043237L (no)	2004-08-02	Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
EP1643986A4 (en)	2009-04-08	PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20053211D0 (no)	2005-06-30	Forbindelser for behandling av metabolske forstyrrelser.
NO20053384L (no)	2005-09-15	Benzazepinderivater for behandling av neurologiske forstyrrelser.
NL1028087A1 (nl)	2005-07-25	Sulfonamiderivaten voor de behandeling van ziekten.
NL1023692A1 (nl)	2003-12-19	Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
EP1654260A4 (en)	2008-09-24	6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
IL175535A (en)	2016-03-31	Compositions for treatment of neurodegenerative diseases
NL1023691A1 (nl)	2003-12-19	Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
NL1028924A1 (nl)	2005-11-01	Gesubstitueerde morfolineverbindingen voor de behandeling van stoornissen van het centrale zenuwstelsel.
EP1658072A4 (en)	2009-03-25	Compounds for the Treatment of Neurodegenerative Diseases
IL177955A0 (en)	2006-12-31	Sulfonamide compounds for the treatment of neurodegenerative disorders
NL1028599A1 (nl)	2005-09-26	Verbindingen voor de behandeling van ziekten.
NL1033562A1 (nl)	2007-06-21	Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
NL1030418A1 (nl)	2006-05-16	Azabenzoxazolen voor de behandeling van CZS-stoornissen.
NL1032552C2 (nl)	2007-09-25	Imidazoolverbindingen voor de behandeling van neurologische stoornissen.
NL1025044A1 (nl)	2004-06-21	Bicyclische derivaten voor de behandeling van abnormale celgroei.

Legal Events

Date	Code	Title	Description
2004-06-01	AD1A	A request for search or an international type search has been filed
2004-08-02	RD2N	Patents in respect of which a decision has been taken or a report has been made (novelty report)	Effective date: 20040610
2004-12-01	PD2B	A search report has been drawn up
2008-07-01	VD1	Lapsed due to non-payment of the annual fee	Effective date: 20080501